163 related articles for article (PubMed ID: 33720401)
1. Determination of salmeterol, α-hydroxysalmeterol and fluticasone propionate in human urine and plasma for doping control using UHPLC-QTOF-MS.
Sakellariou P; Petrou M; Lyris E; Tsivou M; Fragkaki A; Kiousi P; Angelis YS; Pistos C
Biomed Chromatogr; 2021 Aug; 35(8):e5114. PubMed ID: 33720401
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of salmeterol and its main metabolite α-hydroxysalmeterol after acute and chronic dry powder inhalation in exercising endurance-trained men: Implications for doping control.
Jessen S; Becker V; Rzeppa S; Backer V; Bengtsen KH; Hullstein I; Dehnes Y; Hostrup M
Drug Test Anal; 2021 Apr; 13(4):747-761. PubMed ID: 33210444
[TBL] [Abstract][Full Text] [Related]
3. Development of a sensitive method for simultaneous determination of fluticasone propionate and salmeterol in plasma samples by liquid chromatography-tandem mass spectrometry.
Silvestro L; Savu SR; Savu SN; Tudoroniu A; Tarcomnicu I
Biomed Chromatogr; 2012 May; 26(5):627-35. PubMed ID: 22577660
[TBL] [Abstract][Full Text] [Related]
4. Rapid chiral high-performance liquid chromatographic assay for salmeterol and alpha-hydroxysalmeterol. Application to in vitro metabolism studies.
Zhang M; Fawcett JP; Shaw JP
J Chromatogr B Biomed Sci Appl; 1999 Jun; 729(1-2):225-30. PubMed ID: 10410946
[TBL] [Abstract][Full Text] [Related]
5. The salmeterol anomaly and the need for a urine threshold.
Jacobson GA; Hostrup M
Drug Test Anal; 2022 Jun; 14(6):997-1003. PubMed ID: 32314556
[TBL] [Abstract][Full Text] [Related]
6. Enantioselective disposition of (R)-salmeterol and (S)-salmeterol in urine following inhaled dosing and application to doping control.
Jacobson GA; Hostrup M; Narkowicz CK; Nichols DS; Haydn Walters E
Drug Test Anal; 2017 Aug; 9(8):1262-1266. PubMed ID: 28033454
[TBL] [Abstract][Full Text] [Related]
7. Simultaneous quantitative determinations of fluticasone propionate and salmeterol xinafote in diskus inhalers.
Duran A; Dogan HN; Ulgen M
Drug Metab Lett; 2014; 8(1):31-5. PubMed ID: 25313021
[TBL] [Abstract][Full Text] [Related]
8. Investigation of interaction between salmeterol and fluticasone propionate and its effect on quantitative accuracy of an LC/MS/MS assay in human plasma at low pg/mL concentrations.
Carter SJ; Cápka V
J Chromatogr B Analyt Technol Biomed Life Sci; 2008 Dec; 876(2):163-9. PubMed ID: 19010742
[TBL] [Abstract][Full Text] [Related]
9. The aliphatic oxidation of salmeterol to alpha-hydroxysalmeterol in human liver microsomes is catalyzed by CYP3A.
Manchee GR; Eddershaw PJ; Ranshaw LE; Herriott D; Park GR; Bayliss MK; Tarbit MH
Drug Metab Dispos; 1996 May; 24(5):555-9. PubMed ID: 8723736
[TBL] [Abstract][Full Text] [Related]
10. Minimizing matrix effects in the development of a method for the determination of salmeterol in human plasma by LC/MS/MS at low pg/mL concentration levels.
Cápka V; Carter SJ
J Chromatogr B Analyt Technol Biomed Life Sci; 2007 Sep; 856(1-2):285-93. PubMed ID: 17625989
[TBL] [Abstract][Full Text] [Related]
11. Clinical pharmacokinetics of salmeterol.
Cazzola M; Testi R; Matera MG
Clin Pharmacokinet; 2002; 41(1):19-30. PubMed ID: 11825095
[TBL] [Abstract][Full Text] [Related]
12. Quantitative detection of inhaled salmeterol in human urine and relevance to doping control analysis.
Deventer K; Pozo OJ; Delbeke FT; Van Eenoo P
Ther Drug Monit; 2011 Oct; 33(5):627-31. PubMed ID: 21912333
[TBL] [Abstract][Full Text] [Related]
13. Inhaled salmeterol/fluticasone propionate combination: a pharmacoeconomic review of its use in the management of asthma.
Lyseng-Williamson KA; Plosker GL
Pharmacoeconomics; 2003; 21(13):951-89. PubMed ID: 12959627
[TBL] [Abstract][Full Text] [Related]
14. A short-term comparison of fluticasone propionate/salmeterol with ipratropium bromide/albuterol for the treatment of COPD.
Donohue JF; Kalberg C; Emmett A; Merchant K; Knobil K
Treat Respir Med; 2004; 3(3):173-81. PubMed ID: 15219176
[TBL] [Abstract][Full Text] [Related]
15. Simultaneous analysis of glucocorticosteroid fluticasone propionate and its metabolite fluticasone propionate 17β-carboxylic acid in human plasma by UPLC-MS/MS at sub pg/mL level.
Nair SG; Patel DP; Sanyal M; Singhal P; Shrivastav PS
J Pharm Biomed Anal; 2017 Feb; 135():1-7. PubMed ID: 27987390
[TBL] [Abstract][Full Text] [Related]
16. Inhaled salmeterol/fluticasone propionate combination: a review of its use in persistent asthma.
Markham A; Jarvis B
Drugs; 2000 Nov; 60(5):1207-33. PubMed ID: 11129128
[TBL] [Abstract][Full Text] [Related]
17. Salmeterol and fluticasone propionate given as a combination. Lack of systemic pharmacodynamic and pharmacokinetic interactions.
Kirby S; Falcoz C; Daniel MJ; Milleri S; Squassante L; Ziviani L; Ventresca GP
Eur J Clin Pharmacol; 2001; 56(11):781-91. PubMed ID: 11294367
[TBL] [Abstract][Full Text] [Related]
18. Additive effects of salmeterol and fluticasone or theophylline in COPD.
Cazzola M; Di Lorenzo G; Di Perna F; Calderaro F; Testi R; Centanni S
Chest; 2000 Dec; 118(6):1576-81. PubMed ID: 11115442
[TBL] [Abstract][Full Text] [Related]
19. Inhaled salmeterol/fluticasone propionate: a review of its use in asthma.
Reynolds NA; Lyseng-Williamson KA; Wiseman LR
Drugs; 2005; 65(12):1715-34. PubMed ID: 16060707
[TBL] [Abstract][Full Text] [Related]
20. Determination of salmeterol in rat and dog plasma by high-performance liquid chromatography with fluorescence detection.
Colthup PV; Young GC; Felgate CC
J Pharm Sci; 1993 Mar; 82(3):323-5. PubMed ID: 8095543
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
